Context
After more than ten years within the Cancer Research Center of Lyon, two teams dedicated to liver research emerged
i) the team « Hepatitis viruses and pathobiology of chronic liver diseases », led by Prof Zoulim, and
ii) the team « Epigenetics, microenvironment and liver diseases » led by Prof Levrero and Dr Zeisel.
In 2022, the two teams have been at the inception of the Institute of Hepatology of Lyon (IHL) which evolved successfully to create the Hospital/University Institute EVEREST (Integrative Research in Hepatology) in 2023.
These two teams have founded the new research unit dedicated to liver research named « Pathobiology and Therapy of Liver Diseases – PaThLiv» which will be attached to the world class IHU EVEREST awarded a 20 M€ grant from the French National Agency (ANR).
The research unit, led by Professor Fabien ZOULIM, is composed of 2 teams:
- HeLiP
- EpiLiv
A research Support team composed of 6 technicians and engineers providing administrative, financial, and logistics supports the daily life activities of the PaThLiv unit.
The research unit is built on established scientists including virologists, molecular and cellular biologists, and clinical scientists (hepatologists and liver surgeons). The research unit benefits from already established and longstanding links with the Lyon Universitary Hospital (the Hepatology Service, the Liver Surgery Service, the ICU, and the Clinical Research Center (CRC)). 19 clinicians and surgeons are already affiliated to the two teams of PaThLiv.
« Hepatitis Viruses and Liver Pathogenesis »
(HeLiP)
Dr Barbara TESTONI – Director
Pr Fabien ZOULIM – Deputy Director
« Epigenetics, Microenvironment and Liver Diseases» (EpiLiv)
Pr Massimo LEVRERO – Director
Dr Mirjam ZEISEL – Deputy Director
The PaThLiv unit works in synergy with the new IHU EVEREST – Institute of hepatology.
Scientific objectives
Our scientific vision is to address the most relevant challenges, through high-technology platforms and multidisciplinary expertise, with the following aims:
Objective 1
Objective 2
Objective 3
Objective 4
Objective 5
Identification of novel cure therapies for CHB and CHD;
Comprehensive blueprint profiling and therapeutic innovation for patients with metabolic liver diseases;
Development of new approaches for HCC profiling to accompany the development of combination therapies and enable treatment personalization;
Identification of biomarkers of disease progression in ESLD (including mainly ALD) to improve outcomes and access to transplantation;
Improving liver graft quality through organ perfusion.
PaThLiv in figures
Research teams
Researchers and Scientists
Clinical departments
Clinicians